Elite Pharmaceuticals, Inc. (ELTP) Total liabilities 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) total liabilities at each fiscal year-end, per SEC filings.
$39.4MFY2026 · since FY2017: $8.6M → $39.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $39.4M | -8.1% |
| FY2025 | $42.9M | +64.4% |
| FY2024 | $26.1M | +118.4% |
| FY2023 | $11.9M | +20.2% |
| FY2022 | $9.9M | -1.1% |
| FY2021 | $10.0M | -29.8% |
| FY2020 | $14.3M | +10.0% |
| FY2019 | $13.0M | +4.8% |
| FY2018 | $12.4M | +43.5% |
| FY2017 | $8.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net incomeELTP Net marginELTP Gross profitELTP Gross marginELTP Operating incomeELTP Operating marginELTP Operating cash flowELTP Free cash flowELTP Capital expendituresELTP Return on equityELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Shareholders’ equityELTP overview →